Digestive Diseases and Sciences

, Volume 55, Issue 7, pp 1975–1981

JC Virus T-Antigen DNA in Gastrointestinal Mucosa of Immunosuppressed Patients: A Prospective, Controlled Study

  • Doron Boltin
  • Alex Vilkin
  • Zohar Levi
  • Ori Elkayam
  • Yaron Niv
Original Article



JC virus (JCV), a polyoma virus, is the etiological agent of progressive multifocal leukoencephalopathy in immunosuppressed patients. JCV T-Ag has proven oncogenic potential and is expressed in colonic polyps and carcinomas. We proposed that the prevalence of JCV T-Ag DNA is higher in the normal gastrointestinal (GI) mucosa of immunosuppressed patients compared with their immunocompetent counterparts.


To look for JCV T-Ag DNA in the normal gastrointestinal mucosa of immunosuppressed patients compared with immunocompetent controls.


Macroscopically normal samples of upper and lower GI mucosa were obtained from 38 immunosuppressed patients. A control group included samples from 19 immunocompetent inflammatory bowel disease (IBD) and 29 non-IBD cases. DNA was extracted and polymerase chain reaction (PCR) was performed using primers specific for T-Ag.


JCV T-Ag DNA was found in nine of the immunosuppressed patients (23.7%) and in three of the controls (6.3%; P = 0.02). Transplant recipients had a particularly high prevalence of JCV T-Ag DNA (35.3%). Patients with IBD receiving immunosuppressive drugs had a higher prevalence of JCV T-Ag DNA in comparison with IBD patients who did not receive immunosuppression (22.2% versus 10.5%, respectively), but this difference was not statistically significant (P = 0.574).


JCV T-Ag DNA is more prevalent in the upper and lower GI mucosa of immunosuppressed patients, possibly indicating that the virus resides in these patients. This may account for the higher prevalence of GI carcinomas in immunosuppressed patients.


JC virus T-Ag Immunosuppression Gastrointestinal mucosa 


  1. 1.
    Tibbles LA. Reducing the risk of viral infection in renal transplantation. Transplant Proc. 2008;40(10 Suppl):S48–S51.CrossRefPubMedGoogle Scholar
  2. 2.
    Morrison VA, Rai KR, Peterson BL. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study cancer and leukemia group B 9011. J Clin Oncol. 2001;19:3611–3621.PubMedGoogle Scholar
  3. 3.
    White MK, Khalili K. Polyomaviruses and human cancer: Molecular mechanisms underlying patterns of tumorigenesis. Virology. 2004;324:1–16.CrossRefPubMedGoogle Scholar
  4. 4.
    Raj GV, Gallia GL, Chang CF, Khalili K. T-antigen-dependent transcriptional initiation and its role in the regulation of human neurotropic JC virus late gene expression. J Gen Virol. 1998;79:2147–2155.PubMedGoogle Scholar
  5. 5.
    Kitamura T, Kunitake T, Guo J, et al. Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J Clin Microbiol. 1994;32:2359–2363.PubMedGoogle Scholar
  6. 6.
    Rossi A, Delbue S, Mazziotti R, et al. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol. 2007;79:408–412.CrossRefPubMedGoogle Scholar
  7. 7.
    Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: Implications for viral latency. J Virol. 1996;70:7004–7012.PubMedGoogle Scholar
  8. 8.
    Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(Suppl 2):S180–S186.CrossRefPubMedGoogle Scholar
  9. 9.
    Delbue S, Branchetti E, Boldorini R, et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol. 2008;80:2147–2152.CrossRefPubMedGoogle Scholar
  10. 10.
    Elsner C, Dorries K. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology. 1992;191:72–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Dorries K. Progressive multifocal leucoencephalopathy: Analysis of JC virus DNA from brain and kidney tissue. Virus Res. 1984;1:25–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol. 1999;5:125–133.CrossRefPubMedGoogle Scholar
  13. 13.
    Monaco MC, Jensen PN, Hou J. Detection of JC virus DNA in human tonsil tissue: Evidence for site of initial viral infection. J Virol. 1998;72:9918–9923.PubMedGoogle Scholar
  14. 14.
    Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain. 1958;81:93–111.CrossRefPubMedGoogle Scholar
  15. 15.
    Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17:658–665.CrossRefPubMedGoogle Scholar
  16. 16.
    Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30:90–98.CrossRefPubMedGoogle Scholar
  17. 17.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive Multifocal leucoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374.CrossRefPubMedGoogle Scholar
  18. 18.
    Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive Multifocal Leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;35:375–381.CrossRefGoogle Scholar
  19. 19.
    Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.CrossRefPubMedGoogle Scholar
  20. 20.
    Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E. Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. J Med Virol. 1997;52:235–242.CrossRefPubMedGoogle Scholar
  21. 21.
    Ricciardiello L, Laghi L, Ramamirtham P. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology. 2000;119:1228–1235.CrossRefPubMedGoogle Scholar
  22. 22.
    Jung WT, Li MS, Goel A, Boland CR. JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer. 2008;112:1028–1036.CrossRefPubMedGoogle Scholar
  23. 23.
    Selgrad M, Koornstra JJ, Fini L, et al. JC virus infection in colorectal neoplasia that develops after liver transplantation. Clin Cancer Res. 2008;14:6717–6721.CrossRefPubMedGoogle Scholar
  24. 24.
    Niv Y, Goel A, Boland CR. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol. 2005;21:85–89.PubMedGoogle Scholar
  25. 25.
    Enam S, Del Valle L, Lara C, et al. Association of human polyomavirus JCV with colon cancer: Evidence for interaction of viral T-antigen and beta-catenin. Cancer Res. 2002;62:7093–7101.PubMedGoogle Scholar
  26. 26.
    Laghi L, Randolph AE, Chauhan DP, et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA. 1999;96:7484–7489.CrossRefPubMedGoogle Scholar
  27. 27.
    Ricciardiello L, Baglioni M, Giovannini C. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res. 2003;63:7256–7262.PubMedGoogle Scholar
  28. 28.
    Nosho K, Shima K, Kure S, et al. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia. 2009;11:87–95.PubMedGoogle Scholar
  29. 29.
    Goel A, Li MS, Nagasaka T. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology. 2006;130:1950–1961.CrossRefPubMedGoogle Scholar
  30. 30.
    Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol. 2009;47:2388–2391.CrossRefPubMedGoogle Scholar
  31. 31.
    Boland CR, Bigler J, Newcomb PA, Lampe JW, Potter JD. Evidence for an association between JC virus and colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2004;13:2285–2286.PubMedGoogle Scholar
  32. 32.
    Newcomb PA, Bush AC, Stoner GL, Lampe JW, Potter JD, Bigler J. No evidence of an association of JC virus and colon neoplasia. Cancer Epidemiol Biomarkers Prev. 2004;13:662–666.PubMedGoogle Scholar
  33. 33.
    Ricciardiello L, Chang DK, Laghi L, Goel A, Chang CL, Boland CR. Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues. J Virol. 2001;75:1996–2001.CrossRefPubMedGoogle Scholar
  34. 34.
    Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol. 2006;44:13–38.CrossRefPubMedGoogle Scholar
  35. 35.
    Amital A, Shitrit D, Raviv Y. Development of malignancy following lung transplantation. Transplantation. 2006;81:547–551.CrossRefPubMedGoogle Scholar
  36. 36.
    Nagele H, Bahlo M, Klapdor R, Rodiger W, et al. Tumor marker determination after orthotopic heart transplantation. J Heart Lung Transplant. 1999;18:957–962.CrossRefPubMedGoogle Scholar
  37. 37.
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–913.CrossRefPubMedGoogle Scholar
  38. 38.
    Rodriguez-Larrain JM, Ziebert JJ, Kfoury AG, Kuwada S, Taylor DO, Renlund DG. Incidence of adenomatous colorectal polyps in cardiac transplant recipients. Transplantation. 1997;64:528–530.CrossRefPubMedGoogle Scholar
  39. 39.
    Stewart T, Henderson R, Grayson H, Opelz G. Reduced incidence of rectal cancer compared to gastric and colonic cancer, in a population of 73, 076 men and women chronically immunosuppressed. Clin Cancer Res. 1997;3:51–55.PubMedGoogle Scholar
  40. 40.
    Haagsma EB, Hagens VE, Schaapveld M. Increased cancer risk after liver transplantation: A population-based study. J Hepatol. 2001;34:84–91.CrossRefPubMedGoogle Scholar
  41. 41.
    Koornstra JJ, Wesseling J, de Jong AE, Vasen HF, Kleibeuker JH, Haagsma EB. Increased risk of colorectal neoplasia in asymptomatic liver transplant recipients. Gut. 2007;56:892–893.CrossRefPubMedGoogle Scholar
  42. 42.
    Levitsky J, Miller J, Wang E, et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol. 2009;70:146–150.CrossRefPubMedGoogle Scholar
  43. 43.
    Hodge G, Hodge S, Reynolds P, Holmes M. Intracellular cytokines in blood T cells in lung transplant patients—a more relevant indicator of immunosuppression than drug levels. Clin Exp Immunol. 2005;139:159–164.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Doron Boltin
    • 1
    • 2
    • 3
  • Alex Vilkin
    • 2
    • 3
  • Zohar Levi
    • 2
    • 3
  • Ori Elkayam
    • 1
    • 3
  • Yaron Niv
    • 2
    • 3
  1. 1.Department of Internal Medicine 6Tel Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.Department of GastroenterologyRabin Medical CenterPetach TikvaIsrael
  3. 3.Tel Aviv UniversityTel AvivIsrael

Personalised recommendations